Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

COVID19 (SARS-CoV2) vaccination/vaccine

5

X.s Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

1
Last update : 25/07/2021
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Granulomatosis with polyangiitis following Pfizer-BioNTech COVID-19 vaccination.
Modern rheumatology case reports 2023 Jan 03;7;127-129 2023 Jan 03
A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
Kidney international 2021 Oct;100;937-938 2021 Oct
ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2021 Oct;78;611-613 2021 Oct
Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine.
Kidney international reports 2021 Dec;6;3087-3089 2021 Dec
Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination.
Frontiers in immunology 2021;12;762006 2021

Powered by

  • ^
  • Contact
  • Cookies
  • About